Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.
about
Mechanisms of cellular invasion by intracellular parasitesRestoration of IFNγR subunit assembly, IFNγ signaling and parasite clearance in Leishmania donovani infected macrophages: role of membrane cholesterolImipramine is an orally active drug against both antimony sensitive and resistant Leishmania donovani clinical isolates in experimental infectionLeishmania donovani infection enhances lateral mobility of macrophage membrane protein which is reversed by liposomal cholesterolHuman visceral leishmaniasis: decrease in serum cholesterol as a function of splenic parasite load.A current perspective on leishmaniasisCholesterol Corrects Altered Conformation of MHC-II Protein in Leishmania donovani Infected Macrophages: Implication in Therapy.Genetically Modified Live Attenuated Leishmania donovani Parasites Induce Innate Immunity through Classical Activation of Macrophages That Direct the Th1 Response in Mice.Hyperlipidemia offers protection against Leishmania donovani infection: role of membrane cholesterol.A new model of progressive visceral leishmaniasis in hamsters by natural transmission via bites of vector sand fliesLeishmania donovani targets Dicer1 to downregulate miR-122, lower serum cholesterol, and facilitate murine liver infection.Clinical, hematological and biochemical alterations in hamster (Mesocricetus auratus) experimentally infected with Leishmania infantum through different routes of inoculation.Cholesterol lowering drug may influence cellular immune response by altering MHC II function.Liposomal cholesterol delivery activates the macrophage innate immune arm to facilitate intracellular Leishmania donovani killing.Miltefosine Resistant Field Isolate From Indian Kala-Azar Patient Shows Similar Phenotype in Experimental Infection.Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.Lipids: a key player in the battle between the host and microorganisms.Immunomodulatory effects of antileishmanial drugs.Biological network modeling identifies IPCS in Leishmania as a therapeutic target.Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated Leishmania Parasite Vaccines.
P2860
Q27010243-093CAE30-6AF4-4F7C-895A-F30F12FEE26AQ28476834-B4FFC5DB-5BEB-4602-985A-F0B452DC5C42Q28484622-3F22C7DF-2408-4F77-AD09-457AF271A577Q28542482-48E3E198-9827-4375-BE45-E2BF38BA8DBAQ33877648-004FAFAB-6E97-4466-BBFE-7604D8E24316Q33929832-65B3B0AA-6592-45AB-A75C-B73493A96222Q36026687-A2B76682-C472-41C1-94BC-CA846340F654Q36053499-570D2D63-EF02-46D3-8BE4-7C49FA472ED2Q36387245-346BAE9B-BB1E-4832-968A-E0128AE346C6Q36702606-3AF21D51-9DDD-4A23-9B20-5BB7882924D5Q36708313-BD9BAD2D-DFF7-4F21-A469-334D265323B7Q36749036-3BC084D0-5ED3-4485-A396-DDD55D3F959DQ37222694-D1299880-8E4E-4F12-BBDF-BF391B81CFF8Q37546471-D99A45C9-3830-4DFB-AB05-D99E5831A4B8Q40067217-3642D420-95A8-4635-93E8-6E310A47C3B3Q40541534-CF1DEDD3-B103-40F6-9123-8DF2CEF877BEQ41292718-4A4C9BEA-92F5-473E-84BE-EBBE51D2B5B2Q42256063-7309EF01-6EC1-4745-ACC0-9506D9CAA009Q47329114-99878842-8EFE-4263-A4B8-FBA910EB3932Q51372327-720D41EF-5F96-4E62-9AF8-85A01D845212
P2860
Designing therapies against experimental visceral leishmaniasis by modulating the membrane fluidity of antigen-presenting cells.
description
2009 nî lūn-bûn
@nan
2009年の論文
@ja
2009年学术文章
@wuu
2009年学术文章
@zh
2009年学术文章
@zh-cn
2009年学术文章
@zh-hans
2009年学术文章
@zh-my
2009年学术文章
@zh-sg
2009年學術文章
@yue
2009年學術文章
@zh-hant
name
Designing therapies against ex ...... y of antigen-presenting cells.
@en
Designing therapies against ex ...... y of antigen-presenting cells.
@nl
type
label
Designing therapies against ex ...... y of antigen-presenting cells.
@en
Designing therapies against ex ...... y of antigen-presenting cells.
@nl
prefLabel
Designing therapies against ex ...... y of antigen-presenting cells.
@en
Designing therapies against ex ...... y of antigen-presenting cells.
@nl
P2093
P2860
P356
P1476
Designing therapies against ex ...... y of antigen-presenting cells.
@en
P2093
Arun Kumar Haldar
Bikramjit Raychaudhury
June Ghosh
Kshudiram Naskar
Moumita Ghosh
Pradeep Das
Rajan Guha
Ranjan Dhar
P2860
P304
P356
10.1128/IAI.00057-09
P407
P577
2009-03-16T00:00:00Z